18Aug
18Aug
2020 International Canned Wine Competition
The dust has settled and the results are in for the second annual International Canned Wine Competition. Completion of the contest was delayed as more than forty entries were held up in U.S. Customs for reasons known only to Customs clerks, but now all results are in. Archer Roose included on list. Read more >>
14Aug
Kalion Inc. Receives NSF Phase II SBIR Grant to Develop Bio-based Glucaric Acid
Kalion Inc. has been awarded a National Science Foundation (NSF) Phase II Small Business Research (SBIR) grant for $746,822 to conduct research and development work improving the bio-based production of glucaric acid. Glucaric acid and its related compounds enhance sustainability as well as improve the chemical properties of products ranging from water treatment, polymers & textiles, coatings, detergents and pharmaceuticals. Read more >>
11Aug
eSight 4 Earns CE Mark Approval to Bring New Wearable Device to Europe
eSight, a cutting-edge vision enhancement platform, today announces it has received CE Mark approval for eSight 4, the company's latest assistive technology device that's clinically proven to significantly enhance vision for those living with low vision and legal blindness. The CE Mark certification signifies that eSight 4 has been assessed to meet high safety, health and environmental protection requirements in Europe and is considered an essential requirement for companies to sell and distribute medical products within the European Economic Area...
07Aug
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the second quarter of 2020. The Company also provided clinical and corporate updates. Read more >>
06Aug
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Read more >>
05Aug
LaunchPad Medical Rebrands as RevBio and Launches an Updated Website
Executives from LaunchPad Medical, Inc. announced that the company has rebranded. Its new name, RevBio, was chosen since it more accurately portrays the objective of developing its revolutionary Tetranite® bone adhesive biomaterial platform. Read more >>
04Aug
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming conferences. Read more >>
29Jul
Zylö and Grapefruit Forge Partnership That Promises to Disrupt the Topical Cannabis Market
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that it has entered into an exclusive agreement with Grapefruit USA, Inc. to supply its Z-pod™ system as the technological underpinning of Grapefruit’s Hourglass™ time-release cannabinoid topical cream. Read more >>
29Jul